March 2, 2020 / 12:49 PM / a month ago

BRIEF-Gilead To Buy Drug Developer Forty Seven For About $4.9 Bln

March 2 (Reuters) - Gilead:

* GILEAD - FOLLOWING COMPLETION OF TENDER OFFER, CO WILL ACQUIRE ALL REMAINING SHARES NOT TENDERED IN OFFER THROUGH SECOND STEP MERGER

* GILEAD TO ACQUIRE FORTY SEVEN FOR $4.9 BILLION

* GILEAD SCIENCES INC - DEAL FOR $95.50 PER SHARE

* GILEAD SCIENCES - DEAL, WHICH VALUES FORTY SEVEN AT ABOUT $4.9 BILLION, WAS UNANIMOUSLY APPROVED BY BOTH GILEAD AND FORTY SEVEN BOARDS OF DIRECTORS

* GILEAD SCIENCES - A WHOLLY-OWNED UNIT OF GILEAD WILL PROMPTLY COMMENCE TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF FORTY SEVEN’S COMMON STOCK

* GILEAD SCIENCES INC - PLANS TO PAY ALL CASH CONSIDERATION FOR TRANSACTION

* GILEAD SCIENCES - TENDER OFFER IS NOT SUBJECT TO A FINANCING CONDITION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below